The strongest argument against my own position on eu-wide position versus national implementation, stated as well as I can state it, since nobody else has yet.
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did.
Eu-wide position versus national implementation: what I expected, what I found, and the gap between them.
I am posting the gap rather than a theory about it. My theories about gaps like this one have not held up well.
The most useful post in this subcategory is a link to the current national page in its own language, with a date.
Worth checking against a second source before it gets quoted onward.
Coming back to the opening post, because the follow-up matters more than the original answer.
Where the eu-wide position versus national implementation reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Picking up the opening post: that is the part I would want checked first.
I think the eu-wide position versus national implementation question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Where a national body publishes clinical guidance, that document determines the practical answer more than the authorisation does.
It reads as pedantry until the day it does not.
I read post #5 twice before replying, because I had assumed the opposite.
What I would tell a new member reading about eu-wide position versus national implementation for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
The strongest argument against my own position on eu-wide position versus national implementation, stated as well as I can state it, since nobody else has yet.
On post #5 — agreed on the reasoning, with one qualification.
Regional stock held inside the union removes a customs question entirely for intra-union movement, which is a practical difference rather than a legal opinion.
This has been discussed before and I could not find the thread, so, again.
Post #9 answers the question as asked. The question underneath it is different.
An honest declaration on eu-wide position versus national implementation: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
One more thing on eu-wide position versus national implementation that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
This follows post #10 rather than contradicting it.
Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them.
The part I am sure of is shorter than the part I have written.
Appreciated. The plain phrasing does more work here than a longer post would.
Picking up post #14: that is the part I would want checked first.
Eu-wide position versus national implementation is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Coming back to post #16, because the follow-up matters more than the original answer.
The public assessment report published at authorisation is one of the best free technical documents available on any of these compounds and it is rarely cited here.
I am aware this is the third time this month I have made this point.
Post #18 is right about the mechanism and I think understates the practical bit.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
Noting that I have skin in this question and have tried to discount for it.
Worth separating two things that post #16 runs together.
The honest answer on eu-wide position versus national implementation is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
I disagree with the framing of eu-wide position versus national implementation above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Picking up post #23: that is the part I would want checked first.
Practical note on eu-wide position versus national implementation: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
The useful distinction on eu-wide position versus national implementation is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Post #25 is right about the mechanism and I think understates the practical bit.
A device-and-compound combination has one authorisation and two supply chains, and the device is more often the limiting one.
Where a national body publishes clinical guidance, that document determines the practical answer more than the authorisation does.
Reading it again, the caveat matters more than the finding.
On post #25 — agreed on the reasoning, with one qualification.
Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them.
Post #29 answers the question as asked. The question underneath it is different.
Nothing here is medical or legal advice, and this subcategory in particular attracts questions where that matters.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the European Union category
EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+1 | 5 | 18k | 10mo |
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. A methods question rather than a substantive one, about eu-wide position versus national…
|
2 | 54k | 19mo | |
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. Cross-border purchase rules within — I have the observation and I do not trust my…
|
+12 | 16 | 2.8k | 11mo |
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Something about EMA product information does not reconcile and I would like a…
|
+70 | 74 | 7k | 8mo |
|
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. Asking about reimbursement variation across member states directly, because I…
|
+7 | 11 | 39k | 3mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. Working notes on List price versus negotiated price rather than a…
|
+24 | 28 | 50k | 12mo |
|
Second pass at: Manufacturer assistance programmes and their eligibility rules
Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+13 | 17 | 1.8k | 16mo |
|
Irish differences from the UK position — what changed since
Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Irish differences is wrong? I ask…
|
+8 | 12 | 782 | 1d |
|
External review after an internal denial
External review after an internal denial Writing it up because I had to work it out twice and would rather nobody else did. Proposing that external review deserves a maintained page rather than a recurring…
|
2 | 18k | 1mo | |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on cross-border…
|
+6 | 10 | 41k | 11mo |